Nymox Pharma (NYMX) Ramps to Session Highs Following Fexapotide Phase 3 Data

August 24, 2016 3:05 PM EDT

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Nymox Pharma (Nasdaq: NYMX) shares are trading to session highs. The stock is up over 75 percent on the session after the company announced successful new study results from the long-term blinded placebo crossover group from the U.S. Phase 3 trials for fexapotide, the Company's lead compound in late stage development for enlarged prostate (BPH) and for localized prostate cancer.

For more color, click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Momentum Movers, Trader Talk

Add Your Comment